Bioavailability evaluation of compound BL-123 and its salts by high performance liquid chromatography (HPLC) coupled with tandem mass spectrometry

• Grant number: 13/00088-5
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: August 01, 2013
• End date: July 31, 2014
• Field of knowledge: Health Sciences - Pharmacy - Medicines Analysis and Control
• Principal Investigator: Gilberto de Nucci
• Grantee: Juliana Schinzari Palo
• Host Institution: Faculdade de Ciências Médicas (FCM). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

The low amount of antifungal agents that can be used in clinical practice nowadays, plus the fact that fungi are eukaryotes, presenting very small physiological differences when compared to humans, unlikely other non-eukaryotic parasites, turns out to be necessary the existence of more studies contemplating the development of new safe antifungal drugs. There are three classes of antifungal drugs nowadays. The class of amphotericin B presents a very limited use, due to a large amount of significant adverse effects. Echinocandins, on the other hand, have limited use due to their exclusive intravenous administration and a limited range of action. Azoles, in turn, comprehend a large action spectrum and some can be administered orally. The BL-123 is an imidazole of important structural similarity with miconazole. It is in phase 1 of the study to evaluate safety and tolerability, so the objective of this research is to determine the bioavailability of the compound BL-123 through testing in Beagle dogs, as this drug has a great potential to become an effective antifungal therapy. The observation of the high bioavailability of the drug will indicate that it has great systemic effects when administered orally. (AU)